Department of Child and Adolescent Psychiatry, The University of Texas Medical Branch, 301 University Blvd, Galveston, TX, 77555-0188, USA,
Paediatr Drugs. 2014 Oct;16(5):353-61. doi: 10.1007/s40272-014-0088-y.
Depression is a relatively common diagnosis in children and adolescents, and is associated with significant morbidity and suicidality in this population. Evidence-based treatment of the acute illness is imperative to try to prevent the development of treatment-resistant depression or other complications. In situations where response to acute treatment is inadequate, clinicians should first consider factors that may influence outcome, such as psychiatric or medical comorbidities, psychosocial stressors, and treatment noncompliance. Selective serotonin reuptake inhibitors (SSRIs) are the first-line treatment for depression in children and adolescents. For treatment-resistant depression, a switch to an alternate SSRI is recommended before trials of other antidepressants. Psychotherapy, such as cognitive behavioral therapy or interpersonal therapy, may improve treatment response. More research is needed examining medication augmentation strategies for treatment-resistant depression in children and adolescents.
抑郁症在儿童和青少年中是一种相对常见的诊断,与该人群的显著发病率和自杀率相关。对急性疾病进行循证治疗对于预防治疗抵抗性抑郁症或其他并发症至关重要。在急性治疗反应不足的情况下,临床医生应首先考虑可能影响治疗结果的因素,例如精神或医学合并症、心理社会压力源以及治疗不依从。选择性 5-羟色胺再摄取抑制剂 (SSRIs) 是儿童和青少年抑郁症的一线治疗药物。对于治疗抵抗性抑郁症,建议在尝试其他抗抑郁药之前,先转换为另一种 SSRI。心理治疗,如认知行为疗法或人际治疗,可能会改善治疗反应。对于治疗抵抗性抑郁症的药物增效策略,需要更多的研究。